Regulus Therapeutics (NASDAQ: RGLS) Clinical Candidate in HCV Nominated; Reiterate Buy - Needham & Company
Tweet Send to a Friend
Needham & Company reiterated a Buy rating and $8 price target on Regulus Therapeutics (NASDAQ: RGLS) following last night's conference ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
